RealFeedApp beta

D&D Pharmatech enters Phase 2 trials for MASH

The company develops peptide therapeutics for metabolic disorders and fibrosis using proprietary delivery technologies. The lead candidate is in Phase 2 for treating metabolic dysfunction-associated steatohepatitis.

Field
drugs and trials
What they did
D&D Pharmatech has advanced its liver fibrosis drug to the clinical trial phase scheduled for 2027.
Why it matters
This will help people with liver fibrosis, as the drug is designed to treat chronic conditions involving fat accumulation and tissue scarring.
#liver fibrosis#peptide therapeutics#mash#phase 2

Read the original →